ERBB2 and adenocarcinoma: In a recent clinical study of first-line pembrolizumab plus chemotherapy in patients with HER2-negative, LA unresectable or mG/GEJ adenocarcinoma (KEYNOTE-859, NCT03675737), 34.9% of enrolled patients had tumors with a PD-L1 CPS ≥ 10 [34].